Fentanyl Walked—Who Signed Off?

Federal drug agents in New Mexico let suspected fentanyl loads keep moving to build bigger cases, and now multiple watchdogs and lawmakers want the paper trail.

Story Snapshot

Whistleblowers allege agents allowed large fentanyl shipments to proceed in New Mexico.
Drug Enforcement Administration asked the inspector general to review its actions.
Justice Department’s Office of Professional Responsibility earlier found such decisions “reasonable” under guidance.
New Mexico’s attorney general sued for records, citing public safety concerns.

What Triggered The New Scrutiny

Whistleblower filings alleged that, in 2023, federal prosecutors told Drug Enforcement Administration agents in New Mexico not to stop vehicles believed to be moving fentanyl. The Office of Special Counsel forwarded a complaint to the Attorney General, who sent it to the Justice Department’s Office of Professional Responsibility for review. Reporting and whistleblower accounts described hundreds of thousands of pills left unseized across several operations to target higher-level traffickers. Those claims pushed the issue into public view and prompted fresh oversight steps.

The Drug Enforcement Administration asked the Justice Department’s inspector general to conduct a review focused on how the agency handled these fentanyl cases and the whistleblower complaint. The request followed national reporting that detailed “fentanyl walking” as an investigative tactic in New Mexico. The inspector general’s review will examine how personnel weighed risks, who approved delays or declines of interdiction, and how those decisions were documented or reviewed after the fact.

What The Government Has Already Said On The Merits

The Justice Department’s Office of Professional Responsibility issued a 2024 summary stating that, in the matters it reviewed, decisions not to seize suspected fentanyl right away had adequate oversight and were reasonable given the circumstances. The summary said the conduct did not violate fentanyl guidance or a law, rule, or regulation and did not pose a “substantial and specific danger” to public health and safety. The guidance permits teams to balance short-term risks against long-term investigative goals under supervision.

The Drug Enforcement Administration has also pushed back on the public framing. The agency said claims that it knowingly let fentanyl reach communities are false and misstate the facts. It maintained that the decisions at issue were lawful, reasonable under the circumstances, and aligned with department guidance. That stance underscores a core tension: investigators say they used accepted methods; critics say those choices gambled with lives during a deadly overdose wave.

Why New Mexico’s Officials Are Demanding Records

New Mexico Attorney General Raúl Torrez sued the United States Department of Justice to obtain records about these operations. His office said federal officials wrongly denied requests for policies, reports, and communications tied to unseized fentanyl shipments. Torrez argues the public needs to see who approved the calls and how risks were managed, and he has warned the findings could drive further legal action by the state. The lawsuit seeks transparency after months of refusals or narrow disclosures.

Every seven minutes, fentanyl takes another American life.

Somebody's daughter. Somebody's dad. Somebody's best friend. On National Overdose Awareness Day, Empower Oversight remembers them and demands accountability.

Empower Oversight's client, DEA Special Agent David Howell,… pic.twitter.com/FkWz9TPOTS

— Empower Oversight (@EMPOWR_us) August 31, 2026

Members of New Mexico’s congressional delegation asked Drug Enforcement Administration leadership for documents and explanations about interdiction decisions in the state. Their letter cited whistleblower allegations that at least 1.8 million pills went unseized from 2023 to 2025 while agents tried to map a larger network. House Republicans have also pressed for answers, framing the matter as a potential breakdown in safeguards meant to protect the public during complex investigations.

How This Fits Longstanding Drug Tactics—and Today’s Doubts

Federal drug cases sometimes use controlled deliveries and monitored non-intervention to reach higher targets. Courts have recognized these tactics when they include clear oversight, triggers, and documentation. The dispute in New Mexico turns on whether those safeguards were strong enough, whether public safety risks were truly minimized, and whether officials recorded and reviewed the tradeoffs as the guidance requires. The inspector general’s findings will be key to settling that question across agencies.

What Matters For Readers Across The Spectrum

Families dealing with addiction see a system that too often fails to stop poison on time. Taxpayers see secrecy and red tape while overdose deaths remain high. Agents say they need room to dismantle cartels, but communities want proof that guardrails were real, not just on paper. Transparent records, clear approval chains, and after-action reviews can show whether this was smart policing or reckless risk. The pending oversight reviews aim to deliver that clarity.